Who is sponsoring NCT06207786?

NCT06207786 is sponsored by Mayo Clinic.

What condition does NCT06207786 study?

NCT06207786 studies Skin Cancer, Skin Cancer Face, Malignant Cutaneous Adnexal Neoplasm.

What drugs are being tested in NCT06207786?

Interventions: Povidone-Iodine Swabs, Staphylococcus nasal swab, Antibiotic.

What is the status of NCT06207786?

NCT06207786 is currently WITHDRAWN.

Last reviewed 2024-11-21 · How we verify

Efficacy of Intranasal Povidone Iodine Swab Versus Oral Antibiotic Prophylaxis to Prevent Surgical Site Infections in Patients Undergoing Mohs Micrographic Surgery

NCT06207786 NA WITHDRAWN

The purpose of this study is to compare surgical site infection rates for patients treated with Mohs micrographic surgery after bilateral nasal swab with povidone iodine versus standard treatment including the use of a standardized oral antibiotic prophylaxis protocol.

Details

Lead sponsor	Mayo Clinic
Phase	NA
Status	WITHDRAWN
Start date	2024-09-01
Completion	2030-05

Conditions

Skin Cancer
Skin Cancer Face
Malignant Cutaneous Adnexal Neoplasm

Interventions

Povidone-Iodine Swabs
Staphylococcus nasal swab
Antibiotic

Primary outcomes

Effectiveness of nasal decolonization with povidone-iodine versus a standardized oral antibiotic prophylaxis protocol to prevent surgical site infection (SSI) — 30 days after MMS
Effectiveness of nasal decolonization will be assessed based on the presence of SSI within 30 days after Mohs micrographic surgery (MMS). SSI is defined by the United States Centers for Disease Control and Prevention as infection of the cutaneous and subcutaneous tissue occurring within 30 days of surgery. Rates of SSI for both treatment arms will be reported.